Randomised, controlled, multinational, multicentre, clinical trial to examine whether HbA1c can improve in type one diabetes patients who continuously use the Paradigm® REAL-Time system with alarm function as compared to patients on multiple injection therapy receiving one six-day period of continuous glucose monitoring - without alarm function (Guardian® REAL-Time Clinical)

2012 ◽  
Author(s):  
J Hermanides
Diabetes Care ◽  
2020 ◽  
Vol 43 (11) ◽  
pp. 2736-2743 ◽  
Author(s):  
Lakshmi G. Singh ◽  
Medha Satyarengga ◽  
Isabel Marcano ◽  
William H. Scott ◽  
Lillian F. Pinault ◽  
...  

2021 ◽  
Vol 5 (4) ◽  
pp. 265-273 ◽  
Author(s):  
Kathryn Beardsall ◽  
Lynn Thomson ◽  
Catherine Guy ◽  
Isabel Iglesias-Platas ◽  
Mirjam M van Weissenbruch ◽  
...  

BMJ Open ◽  
2020 ◽  
Vol 10 (11) ◽  
pp. e040498
Author(s):  
Evelyn Annegret Huhn ◽  
Tina Linder ◽  
Daniel Eppel ◽  
Karen Weißhaupt ◽  
Christine Klapp ◽  
...  

IntroductionReal-time continuous glucose monitoring (rt-CGM) informs users about current interstitial glucose levels and allows early detection of glycaemic excursions and timely adaptation by behavioural change or pharmacological intervention. Randomised controlled studies adequately powered to evaluate the impact of long-term application of rt-CGM systems on the reduction of adverse obstetric outcomes in women with gestational diabetes (GDM) are missing. We aim to assess differences in the proportion of large for gestational age newborns in women using rt-CGM as compared with women with self-monitored blood glucose (primary outcome). Rates of neonatal hypoglycaemia, caesarean section and shoulder dystocia are secondary outcomes. A comparison of glucose metabolism and quality of life during and after pregnancy completes the scope of this study.Methods and analysisOpen-label multicentre randomised controlled trial with two parallel groups including 372 female patients with a recent diagnosis of GDM (between 24+0 until 31+6 weeks of gestation): 186 with rt-CGM (Dexcom G6) and 186 with self-monitored blood glucose (SMBG). Women with GDM will be consecutively recruited and randomised to rt-CGM or control (SMBG) group after a run-in period of 6–8 days. The third visit will be scheduled 8–10 days later and then every 2 weeks. At every visit, glucose measurements will be evaluated and all patients will be treated according to the standard care. The control group will receive a blinded CGM for 10 days between the second and third visit and between week 36+0 and 38+6. Cord blood will be sampled immediately after delivery. 48 hours after delivery neonatal biometry and maternal glycosylated haemoglobin A1c (HbA1c) will be assessed, and between weeks 8 and 16 after delivery all patients receive a re-examination of glucose metabolism including blinded CGM for 8–10 days.Ethics and disseminationThis study received ethical approval from the main ethic committee in Vienna. Data will be presented at international conferences and published in peer-reviewed journals.Trial registration numberNCT03981328; Pre-results.


2015 ◽  
Vol 2 (1) ◽  
pp. 35-41
Author(s):  
Rivan Risdaryanto ◽  
Houtman P. Siregar ◽  
Dedy Loebis

The real-time system is now used on many fields, such as telecommunication, military, information system, evenmedical to get information quickly, on time and accurate. Needless to say, a real-time system will always considerthe performance time. In our application, we define the time target/deadline, so that the system should execute thewhole tasks under predefined deadline. However, if the system failed to finish the tasks, it will lead to fatal failure.In other words, if the system cannot be executed on time, it will affect the subsequent tasks. In this paper, wepropose a real-time system for sending data to find effectiveness and efficiency. Sending data process will beconstructed in MATLAB and sending data process has a time target as when data will send.


Sign in / Sign up

Export Citation Format

Share Document